EUROPA PASA DE TENER DOS TRATAMIENTOS SCLC-ES EN PRIMERA LINEA INMUNOTERAPIA ( ATEZOLIZUMAB
Y DURVALUMAB ) ... A TENER CUATRO ( ATEZOLIZUMAB, DURVALUMAB , SERPLULIMAB Y TISLELIZUMAB ) .
03 marzo 2020
Small Cell Lung Cancer / Lurbinectedin / EEUU . A Multicenter Expanded Access Treatment Protocol of Lurbinectedin in Previously Treated SCLC in the USA .